3/10/2010-Shares of Medtronic (NYSE:MDT) are trading 1.2% lower premarket Wednesday after the Food and Drug Administration said a study looking at the company's "deep-brain stimulation" system in epilepsy patients failed to meet a study goal looking at a reduction in the seizure rate over a three-month period, Dow Jones reported.
Though the agency did acknowledge that patients being treated with the deep brain stimulation system after three months had a greater reduction in seizures compared to patients whose device was not activated.
The device faces a review for use in epilepsy on Friday by the FDA's neurological devices panel, which is composed of non-FDA medical experts.
Medtronic has said epilepsy patients with the device saw a 56% reduction in seizure activity when measured after two years.
Keywords: Medtronic epilepsy study Stock brain smartrend
Ticker(s): MDT
